Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Saved in:
| Title: | Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. |
|---|---|
| Authors: | Gilan O; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Rioja I; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Knezevic K; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Bell MJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Yeung MM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Harker NR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Lam EYN; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Chung CW; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bamborough P; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Petretich M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Urh M; Promega Corporation, Madison, WI, USA., Atkinson SJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bassil AK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Roberts EJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vassiliadis D; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Burr ML; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Preston AGS; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Wellaway C; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Werner T; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gray JR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Michon AM; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gobbetti T; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Kumar V; Computational Biology, GlaxoSmithKline, Collegeville, PA, USA., Soden PE; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Haynes A; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vappiani J; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Tough DF; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Taylor S; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Dawson SJ; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Bantscheff M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Lindon M; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Drewes G; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Demont EH; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Daniels DL; Promega Corporation, Madison, WI, USA., Grandi P; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Prinjha RK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK. mark.dawson@petermac.org rabinder.prinjha@gsk.com., Dawson MA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. mark.dawson@petermac.org rabinder.prinjha@gsk.com.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia. |
| Source: | Science (New York, N.Y.) [Science] 2020 Apr 24; Vol. 368 (6489), pp. 387-394. Date of Electronic Publication: 2020 Mar 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32193360 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gilan+O%22">Gilan O</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Rioja+I%22">Rioja I</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Knezevic+K%22">Knezevic K</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Bell+MJ%22">Bell MJ</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Yeung+MM%22">Yeung MM</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Harker+NR%22">Harker NR</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Lam+EYN%22">Lam EYN</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Chung+CW%22">Chung CW</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Bamborough+P%22">Bamborough P</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Petretich+M%22">Petretich M</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Urh+M%22">Urh M</searchLink>; Promega Corporation, Madison, WI, USA.<br /><searchLink fieldCode="AU" term="%22Atkinson+SJ%22">Atkinson SJ</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Bassil+AK%22">Bassil AK</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Roberts+EJ%22">Roberts EJ</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Vassiliadis+D%22">Vassiliadis D</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Burr+ML%22">Burr ML</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Preston+AGS%22">Preston AGS</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Wellaway+C%22">Wellaway C</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Werner+T%22">Werner T</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Gray+JR%22">Gray JR</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Michon+AM%22">Michon AM</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Gobbetti+T%22">Gobbetti T</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Kumar+V%22">Kumar V</searchLink>; Computational Biology, GlaxoSmithKline, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Soden+PE%22">Soden PE</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Haynes+A%22">Haynes A</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Vappiani+J%22">Vappiani J</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Tough+DF%22">Tough DF</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Taylor+S%22">Taylor S</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Dawson+SJ%22">Dawson SJ</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Bantscheff+M%22">Bantscheff M</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Lindon+M%22">Lindon M</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Drewes+G%22">Drewes G</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Demont+EH%22">Demont EH</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Daniels+DL%22">Daniels DL</searchLink>; Promega Corporation, Madison, WI, USA.<br /><searchLink fieldCode="AU" term="%22Grandi+P%22">Grandi P</searchLink>; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Prinjha+RK%22">Prinjha RK</searchLink>; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK. mark.dawson@petermac.org rabinder.prinjha@gsk.com.<br /><searchLink fieldCode="AU" term="%22Dawson+MA%22">Dawson MA</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. mark.dawson@petermac.org rabinder.prinjha@gsk.com.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220404511%22">Science (New York, N.Y.)</searchLink> [Science] 2020 Apr 24; Vol. 368 (6489), pp. 387-394. <i>Date of Electronic Publication: </i>2020 Mar 19. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+the+Advancement+of+Science%22">American Association for the Advancement of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0404511 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1095-9203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200368075%22">00368075 </searchLink><i>NLM ISO Abbreviation: </i>Science <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32193360 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1126/science.aaz8455 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 387 Titles: – TitleFull: Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gilan O – PersonEntity: Name: NameFull: Rioja I – PersonEntity: Name: NameFull: Knezevic K – PersonEntity: Name: NameFull: Bell MJ – PersonEntity: Name: NameFull: Yeung MM – PersonEntity: Name: NameFull: Harker NR – PersonEntity: Name: NameFull: Lam EYN – PersonEntity: Name: NameFull: Chung CW – PersonEntity: Name: NameFull: Bamborough P – PersonEntity: Name: NameFull: Petretich M – PersonEntity: Name: NameFull: Urh M – PersonEntity: Name: NameFull: Atkinson SJ – PersonEntity: Name: NameFull: Bassil AK – PersonEntity: Name: NameFull: Roberts EJ – PersonEntity: Name: NameFull: Vassiliadis D – PersonEntity: Name: NameFull: Burr ML – PersonEntity: Name: NameFull: Preston AGS – PersonEntity: Name: NameFull: Wellaway C – PersonEntity: Name: NameFull: Werner T – PersonEntity: Name: NameFull: Gray JR – PersonEntity: Name: NameFull: Michon AM – PersonEntity: Name: NameFull: Gobbetti T – PersonEntity: Name: NameFull: Kumar V – PersonEntity: Name: NameFull: Soden PE – PersonEntity: Name: NameFull: Haynes A – PersonEntity: Name: NameFull: Vappiani J – PersonEntity: Name: NameFull: Tough DF – PersonEntity: Name: NameFull: Taylor S – PersonEntity: Name: NameFull: Dawson SJ – PersonEntity: Name: NameFull: Bantscheff M – PersonEntity: Name: NameFull: Lindon M – PersonEntity: Name: NameFull: Drewes G – PersonEntity: Name: NameFull: Demont EH – PersonEntity: Name: NameFull: Daniels DL – PersonEntity: Name: NameFull: Grandi P – PersonEntity: Name: NameFull: Prinjha RK – PersonEntity: Name: NameFull: Dawson MA IsPartOfRelationships: – BibEntity: Dates: – D: 24 M: 04 Text: 2020 Apr 24 Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1095-9203 Numbering: – Type: volume Value: 368 – Type: issue Value: 6489 Titles: – TitleFull: Science (New York, N.Y.) Type: main |
| ResultId | 1 |
